Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
REGENXBIO Inc. (RGNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
Docs: "REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights • Continued progress on ‘5x’25’ strategy to advance five AAV Therapeutics from REGENXBIO’s internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 • ABBV-RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie • Interim results from Phase II AAVIATE® and ALTITUDE® trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation • Additional interim efficacy data from the Phase II AAVIATE and ALTITUDE trials expected at upcoming medical conferences in second half 2023 and first half 2024 • Interim data f..."
02/28/2023 8-K Quarterly results
Docs: "REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights - Continued progress on ‘5x’25’ strategy to advance five AAV Therapeutics from REGENXBIO’s internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 - RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie o Enrollment ongoing in the pivotal ATMOSPHERE® and ASCENT™ clinical trials using subretinal delivery, expected to support BLA filing in 2024 o Recently announced interim data from the Phase II pharmacodynamic study supports use of NAVXpress™ platform process in future commercialization plans o Recently announced cohort expansions in AAVIATE® and ALTITUDE® suprachoroidal clinical tr..."
11/03/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights"
05/04/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
Docs: "REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights"
11/02/2021 8-K Quarterly results
Docs: "REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights"
05/05/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights"
08/07/2019 8-K Quarterly results
Docs: "REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD"
05/07/2019 8-K Quarterly results
Docs: "REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD"
02/27/2019 8-K Quarterly results
08/08/2018 8-K Investor presentation, Quarterly results
Docs: "Table 2: Summary and Comparison of Mean Anti-VEGF Injections Before RGX-314 Administration* After RGX-314 Administration*",
"Presentation Materials"
05/08/2018 8-K Quarterly results
Docs: "REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights"
03/06/2018 8-K Quarterly results
Docs: "REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights"
11/08/2017 8-K Quarterly results
Docs: "REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights"
08/08/2017 8-K Quarterly results
Docs: "REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights"
05/09/2017 8-K Form 8-K - Current report
03/07/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/09/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
03/03/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "REGENXBIO Reports Third Quarter 2015 Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy